Last updated: 2026-09-16 09:05:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Xencor, Inc. (XNCR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $23,85, with a market capitalisation of $1,82B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8,49 to $30,61. This page covers its latest market performance, valuation, price trends and company information.
$1,82B | |
$23,63 | |
$58,35 | |
$5,75 | |
$23,75 | |
4,35K | |
1,20M | |
-- | |
$30,61 | |
$8,49 | |
-- | |
-- |
Xencor, Inc. (XNCR) is trading at $23,85 in pre-market trading as of 2026-09-16 08:56:00, up 0,40% ($0,10) from the previous close of $23,75
Pre-market trading shows how investors are pricing XNCR before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Xencor, Inc. (XNCR) moved from $26,61 to $23,85, representing a decline of 10,39% ($2,76).
The stock traded between $23,36 and $26,76 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,18 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 69,4%
XNCR is currently trading at $23,85, placing it 69,4% of the way from its 52-week low of $8,49 to its 52-week high of $30,61. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 260 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xencor, Inc. (XNCR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.